grant
Virus and Host Directed Immunotherapies for Cure in SHIV-infected Infant Macaques
NIHUS FederalResearch GrantFY20250-11 years old0-4 weeks old21+ years oldAIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAdultAdult HumanAfter CareAfter-TreatmentAftercareAgonistAntibody TherapyBindingBinding SitesBloodBlood Reticuloendothelial SystemBreast FeedingBreast fedBreastfedBreastfeedingCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCell BodyCell surfaceCellsChildChild YouthChildhoodChildren (0-21)Clinical TrialsCombined Modality TherapyCombining SiteControl GroupsDiagnosisDoseEarly treatmentExperimental DesignsGlycansGoalsHIVHIV Envelope Glycoprotein gp120HIV Envelope Protein gp120HIV InfectionsHIV env Protein gp120HTLV-III InfectionsHTLV-III gp120HTLV-III-LAV InfectionsHumanHuman Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsIMPAACTImmune mediated therapyImmune responseImmunologic StimulationImmunological StimulationImmunologically Directed TherapyImmunostimulationImmunotherapeutic agentImmunotherapyInfantInfectionInternational Maternal Pediatric Adolescent AIDS Clinical TrialsInternational Maternal Pediatric Adolescent HIV/AIDS Clinical TrialsInterruptionKnowledgeLAV-HTLV-IIILymph Node Reticuloendothelial SystemLymph node properLymphadenopathy-Associated VirusLymphatic nodesM mulattaM. mulattaMacacaMacaca mulattaMacaca rhesusMacaqueMissionModelingModern ManMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular StereochemistryMultimodal TherapyMultimodal TreatmentNFKB Activation PathwayNHP modelsNewborn InfantNewbornsParticipantPathogenicityPathway interactionsPerinatal InfectionPolysaccharidesPre-Clinical ModelPreclinical ModelsProcessReactive SiteRectumResearchRhesus MacaqueRhesus MonkeySHIVSIVSafetySimian Immunodeficiency VirusesSiteT cell responseT8 CellsT8 LymphocytesTLR7TLR7 geneTestingToll-Like Receptor 7VaccinesViralViral BurdenViral LoadViral Load resultViral reservoirViremiaVirionVirusVirus ParticleVirus reservoirVirus-HIVadulthoodanimal resourceanti-viral developmentanti-viral drug developmentanti-viral immunityanti-viral therapeutic developmentanti-viral therapy developmentantibody based therapiesantibody immunotherapyantibody treatmentantibody-based therapeuticsantibody-based treatmentantiretroviral therapyantiretroviral treatmentantiviral developmentantiviral drug developmentantiviral immunityantiviral therapeutic developmentantiviral therapy developmentcombination therapycombined modality treatmentcombined treatmentcompare to controlcompare treatmentcomparison controlconformationconformationalconformational stateconformationallyconformationsdecay accelerationdeveloping anti-viral agentdeveloping anti-viral drugdeveloping anti-viral therapeuticdeveloping anti-viral therapydeveloping antiviral agentdeveloping antiviral drugdeveloping antiviral therapeuticdeveloping antiviral therapyearly therapyexperimentexperimental researchexperimental studyexperimentsfrontiergp120gp120 ENV Glycoproteingp120(HIV)host responseimmune drugsimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunoresponseimmunotherapeuticsimmunotherapy agentimprovedin vivoinfant infectioninfected infantinhibitorkidslymph glandlymph nodeslymphnodesmulti-modal therapymulti-modal treatmentneutralizing antibodynewborn childnewborn childrennon-human primatenonhuman primatenonhuman primate modelspathwaypediatricperinatal HIVpost treatmentpostnatalprimary outcomeprogramssimian HIVsimian human immunodeficiency virustreatment comparisonviraemiaviral reboundviral sepsisvirus reboundvirusemiayoungster
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
In the quest to identify a widely applicable approach to cure HIV, broadly neutralizing antibodies (bNAbs) have been tested in nonhuman primates (NHPs) and humans, including newborns and children. While encouraging, these studies have not shown a consistent reduction in the size of the persistent viral reservoir compared to antiretroviral therapy…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click